Ind-Swift Laboratories has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA), for the Surveillance GMP inspection of its API manufacturing facility located at Derabassi, Punjab. The USFDA inspection was conducted from March 9, 2020 to March 13, 2020. The EIR has been issued without any Form 483 observations.
This is the sixth successful USFDA inspection completed by the company. The company supplies 15 APIs to its customers based in U.S. The APIs manufactured from the Derabassi Manufacturing facility are supplied across the World to over 70 countries covering more than 280 customers including all the major drug manufacturers across the Globe.
Ind-Swift Laboratories is engaged in the manufacture of Active Pharmaceutical Ingredients (API). The product range of the company includes Macrolide antibiotics, Cardiovascular, Anti histamine, Anti diabetic, Analgesic, Aromatase inhibtors, Anti depressant,Alcohol absistence, etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: